Tata India Pharma & Healthcare Fund - Growth - Regular Plan

  • Previous Nav

  • Net Change on 25-01-2021

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

Investment objective of the scheme is to provide long term capital appreciation by investing predominantly in equity/equity related instruments of the companies in the Pharma&Healthcare sectors in India. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
Tata India Pharma & Healthcare Fund-Regular Plan-Growth 0.56 12.18 57.74 18.52 9.01 8.48
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
NIFTY PHARMA - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Tata India Pharma & Healthcare Fund-Regular Plan-Growth Dec 28, 2015 57.74 18.52 9.01 2.63 419.33
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 63.22 20.19 13.24 2.02 4,383.33
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 62.52 15.05 7.39 2.25 1,575.33
UTI Healthcare Fund - Regular Plan - Growth Option Aug 01, 2005 59.52 15.66 9.51 2.80 649.26

Fund Holdings as on 31-December-2020

  • DR REDDYs LABORATORIES LTD

  • SUN PHARMACEUTICAL INDUSTRIES LTD

  • CIPLA LTD

  • DIVI LABORATORIES LTD

  • NARAYANA HRUDAYALAYA LTD

  • IPCA LABORATORIES LTD

  • ALKEM LABORATORIES LTD

  • LUPIN LTD

  • PROCTER & GAMBLE HEALTH LTD

  • APOLLO HOSPITALS ENTERPRISE LTD

  • SYNGENE INTERNATIONAL LTD

  • (A) TREPS

  • INDOCO REMEDIES LTD

  • AUROBINDO PHARMA LTD

  • J.B.CHEMICALS & PHARMACEUTICALS LTD

  • NATCO PHARMA LTD

  • DR. LAL PATH LABS LTD

  • HEALTHCARE GLOBAL ENTERPRISES LTD

  • GLAND PHARMA LTD

  • ABBOTT INDIA LTD

  • FORTIS HEALTHCARE LTD

  • CADILA HEALTHCARE LTD

  • LAURUS LABS LTD

  • ASTRAZENECA PHARMA INDIA LTD

  • NET CURRENT LIABILITIES

View More
  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

View More

Fund Manager

  • Cash

  • Equity

View More

About Tata India Pharma & Healthcare Fund

Scheme Analysis

Tata India Pharma & Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Tata Mutual Fund. It was launched on 28-Dec-2015 and currently has an AUM of ₹419.33 crore. Tata India Pharma & Healthcare Fund is benchmarked against NIFTY 50 - TRI as primary index and NIFTY PHARMA - TRI as secondary index.

The NAV of Tata India Pharma & Healthcare Fund ended up ₹0.18(1.2%)yesterday to ₹15.1264.

Among its top 3 holdings the fund has exposure to DR REDDYs LABORATORIES LTD, and

The Tata India Pharma & Healthcare Fund is managed by Meeta Shetty and Rahul Singh (Tata).

Fund House Contact

1903, B Wing, Parinee Crescenzo, G Block, Bandra Kurla Complex, Bandra East, Mumbai - 400 051

+91 (22) 66578282
kiran@tataamc.com
+91 (22) 22613782